Device Area
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Abbott started 2026 as it ended 2025 – with major regulatory breakthroughs for pulsed field ablation innovations, boosting its EP credentials in the US and EU. It also broadened its IVDs platform by adding cancer detection and screening company Exact Sciences in a deal expected to close in Q2.
BioStem Technologies’ buyout of BioTissue Holding’s surgical and wound-care business adds cryopreserved and sterile technologies, Cryotek and SteriTek, and a direct sales force focused on acute care settings.
Abbott’s newly CE-marked TactiFlex Duo dual-ablation catheter used for treating AFib is competing against products already introduced by Boston Scientific, J&J and Medtronic.
The US FDA has issued an early alert concerning some Axios stent and delivery systems used in endoscopic drainage procedures after receiving reports of serious injuries and deaths linked to the device.
Amid the spectacle of humanoid robots at CES 2026, Swedish medical simulation company Surgical Science opted for a quieter pitch for its suitcase-sized robotic surgery simulator aimed at taking training out of the OR.
The US FDA has sent warning letters to four companies that it says distribute HIV sample collection kits for home use without proper regulatory authorization.
Atul Gupta, MD and CMO of Royal Philips’ Diagnosis & Treatment business, shares his views about potential developments in imaging and wider medtech in 2026 and the value of AI. He warns that clinicians will not adopt AI they don’t trust, understand or find helpful in real-world conditions.
Boston Scientific’s $14.5bn Deal Folds Penumbra Thrombectomy Platforms Into Cardiovascular Franchise
Subject to shareholder approval,Boston Scientific will acquire Penumbra for approximately $11bn in cash on hand and new debt, and issue 41 million shares for the remaining $4bn.
After receiving the FDA nod for the first in-ear EEG device for brain monitoring, Noax plans four clinical trials in the US focused on epilepsy and is looking for audio company partners to integrate the same tech for use by consumers to monitor their brain activity, the company told Medtech Insight.
MIT-scientist turned entrepreneur Christin Glorioso founded start-up NeuroAge Therapeutics to reverse brain aging and fight dementia.
In this first roundup from CES, Medtech Insight shines a light on AI-powered technologies that help the aging population live healthier and stay independent longer.
Johnson & Johnson is seeking marketing authorization from the US FDA for its Ottava surgical robot for upper abdomen procedures. If granted, Ottava could prove stiff competition for Medtronic and Intuitive.
The MAGiC catheter works with Stereotaxis’ robotic magnetic navigation technology, which allows physicians to steer catheters through the heart with precision and stability.
A pair of diagnostic developers backed with venture capital have teamed up with the University of Tennessee to fight colorectal cancer. The collaboration seeks to advance next generation testing to catch one of the deadliest cancers in its earliest stages.
The one-time implant for patients with nonvalvular atrial fibrillation, Conformal Medical’s CLAAS, reduces stroke risk by preventing blood clot formation in the LAA and cutting the need for long-term oral anticoagulation therapy. Gore’s purchase sees it enter a $7bn market.
Withings announced at CES that its health monitoring app will integrate data from Abbott’s OTC CGM Lingo starting in Q1.
Timed to debut during this week’s CES 2026 technology conference in Las Vegas, the new feature within Abbott’s Libre glucose monitoring software uses generative artificial intelligence to predict how food choices may affect glucose levels.
Medtech Insight spoke with CTA board member Carlos Nunez and AARP’s Andy Miller about what to expect at this year’s CES.
Last year was a busy one for the medtech industry, with major advances in technology as well as big changes at regulatory agencies. Get a peek at the stories our readers couldn't miss.